Real life adherence of chronic hepatitis B patients to entecavir treatment

Digestive and Liver Disease

Volumn 47, Issue 7, 2015, Pages 577-583

  van Vlerken, Lotte G ^a   Arends, Pauline ^b   Lieveld, Faydra I ^a   Arends, Joop E ^a   Brouwer, Willem Pieter ^b   Siersema, Peter D ^a   Janssen, Harry L ^b,c   van Erpecum, Karel J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Beliefs about medicine; Compliance; Hepatitis B virus; Real time medication monitoring

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS B; DRUG MONITORING; FEMALE; HEALTH BELIEF; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VIRUS LOAD; ADOLESCENT; AGE; ANALOGS AND DERIVATIVES; ATTITUDE TO HEALTH; CLINICAL TRIAL; DRUG ADMINISTRATION; HEPATITIS B, CHRONIC; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANINE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937634417     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.03.024     Document Type: Article

References (34)

1. Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30:2212-2219.
2. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.
3. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49:S45-S55.
4. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
5. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 2006, 354:1001-1010.
6. Snow-Lampart A., Chappell B., Curtis M., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
7. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
8. Hongthanakorn C., Chotiyaputta W., Oberhelman K., et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011, 53:1854-1863.
9. Ha N.B., Ha N.B., Garcia R.T., et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Digestive Diseases and Sciences 2011, 56:2423-2431.
10. Kamezaki H., Kanda T., Wu S., et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scandinavian Journal of Gastroenterology 2011, 46:1111-1117.
11. Caro J.J., Salas M., Speckman J.L., et al. Persistence with treatment for hypertension in actual practice. Canadian Medical Association Journal 1999, 160:31-37.
12. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. British Journal of Clinical Pharmacology 2005, 59:564-573.
13. Bramley T.J., Gerbino P.P., Nightengale B.S., et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. Journal of Managed Care Pharmacy 2006, 12:239-245.
14. Hayen A., Bell K., Glasziou P., et al. Monitoring adherence to medication by measuring change in blood pressure. Hypertension 2010, 56:612-616.
15. Nachega J.B., Hislop M., Nguyen H., et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. Journal of Acquired Immune Deficiency Syndromes 2009, 51:65-71.
16. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000, 133:21-30.
17. Marcellin P., Chousterman M., Fontanges T., et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver International 2011, 31:516-524.
18. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012, 57:167-185.
19. https://real.evalan.com/sensemedic_research/.
20. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Medical Care 1992, 30:473-483.
21. Horne R., Weinman J., The Hankins M. Beliefs about Medicines Questionnaire (BMQ): the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology & Health 1998, 14:1-24.
22. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research 1999, 47:555-567.
23. Horne R., Parham R., Driscoll R., et al. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflammatory Bowel Diseases 2009, 15:837-844.
24. Aikens J.E., Nease D.E., Nau D.P., et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Archives of Family Medicine 2005, 3:23-30.
25. Horne R., Cooper V., Gellaitry G., et al. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. Journal of Acquired Immune Deficiency Syndromes 2007, 45:334-341.
26. Menckeberg T.T., Bouvy M.L., Bracke M., et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. Journal of Psychosomatic Research 2008, 64:47-54.
27. Lieveld F.I., van Vlerken L.G., Siersema P.D., et al. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Annals of Hepatology 2013, 12:380-391.
28. Chotiyaputta W., Peterson C., Ditah F.A., et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. Journal of Hepatology 2011, 54:12-18.
29. Chotiyaputta W., Hongthanakorn C., Oberhelman K., et al. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs (VBT). Journal of Viral Hepatitis 2012, 19:205-212.
30. Hilleret M.N., Larrat S., Stanke-Labesque F., et al. Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough. Journal of Hepatology 2011, 55:1468-1469.
31. Berg T., Marcellin P., Zoulim F., et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010, 139:1207-1217.
32. Sogni P., Carrieri M.P., Fontaine H., et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antiviral Therapy 2012, 17:395-400.
33. Vrijens B., Tousset E., Rode R., et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. Journal of Clinical Pharmacology 2005, 45:461-467.
34. Vrijens B., Goetghebeur E. The impact of compliance in pharmacokinetic studies. Statistical Methods in Medical Research 1999, 8:247-262.